From gene target
to go/no-go.
In hours.
Gene therapy programmes spend weeks assembling a feasibility memo before committing to a target. Mishale computes that complete computational feasibility memo — target rationale, guide selection, off-target safety, vector fit, dosing, regulatory pathway — from a single input, in a day.
Sample output · BCL11A programme
Gene therapy design is
the bottleneck.
Not biology.
Casgevy — the first approved CRISPR therapy — took eleven years to reach patients. The biology was understood in 2012. The bottleneck was design, safety characterisation, and regulatory preparation. That work is still done manually. We compute it.
Weeks of manual work
To judge whether a target is even worth pursuing, teams pull guide scores from separate tools, hunt the literature for dosing precedents, and write up vector and regulatory rationale by hand. It takes weeks — with no audit trail and no easy way to compare options.
Committing before you know
Lab and manufacturing budgets get committed before anyone has rigorously checked guide options, off-target risk, vector fit, and dosing. A weak target discovered late costs months and millions — the most expensive way to learn 'no'.
No comparable answer
Every team writes up feasibility differently, so targets and programmes can't be compared on a common basis. There's no consistent, sourced go/no-go read to take to a partner, an investor, or your own portfolio review.
Mishale is the computational infrastructure layer that gene therapy programmes are missing.
One input — gene target + indication. Six sections. decision-ready in hours. Every decision traceable to a data source. Every assumption documented.
Computational
Feasibility Memo.
Six structured sections. Every programme. Computed from a proprietary biological knowledge base spanning genes, variants, approved therapies, and regulatory precedents.
Target Rationale
Is this gene the right target?
Mechanism class, inheritance pattern, therapeutic modality fit, and target confidence score — assessed against our proprietary biological knowledge base and approved therapy precedents.
Three layers.
One output.
A biological knowledge graph. A computational design engine. A structured output layer. Together they reduce weeks of manual work to a single query.
The Biological Foundation
A comprehensive, continuously updated graph of human genes, variants, cell types, approved therapies, and regulatory precedents — assembled from leading biological and clinical databases.
Computational Reasoning
Queries the knowledge graph in real time, runs safety analysis across the reference genome, scores guide candidates against the target profile, and applies dosing and regulatory logic against curated precedent libraries.
The Output Layer
Six structured sections assembled into a decision-ready PDF in under 24 hours. Every field traceable to a source. Every decision documented with a confidence score and biological rationale.
Request a Feasibility Memo.
Tell us the gene target and indication. We'll run the full pipeline and deliver a decision-ready package within 24 hours.
We work with pharma BD teams, biotech founders, and academic translational groups.
contact@mishale.bio · (740) 272-4979 · 2810 North Church St, STE 88597, Wilmington, DE 19802